Company Overview of Neurotech Pharmaceuticals, Inc.
Neurotech Pharmaceuticals, Inc., a biotechnology company, develops sight-saving therapeutics for chronic retinal diseases in the United States. It offers NT-501, which is used for the treatment of geographic atrophy associated with atrophic age-related macular degeneration and retinitis pigmentosa; encapsulated cell technology platform, which allows sustained delivery of therapeutic factors to the back of the eye; and Neurotech Recovery-Back device that controls and treats back pain using transcutaneous electrical nerve stimulation and neuromuscular electrical stimulation. Neurotech Pharmaceuticals, Inc. was formerly known as Neurotech S.A and changed its name in May 2006. The company was fo...
701 George Washington Highway
Lincoln, RI 02865
Founded in 1995
Key Executives for Neurotech Pharmaceuticals, Inc.
Chief Financial Officer and Vice President
Vice President of Core Technology Development
Compensation as of Fiscal Year 2013.
Neurotech Pharmaceuticals, Inc. Key Developments
Neurotech Pharmaceuticals, Inc. Announces New Appointments
Sep 19 13
Neurotech Pharmaceuticals, Inc. announced that renowned ophthalmology experts Eugene de Juan, Jr., M.D., and Lester Kaplan, Ph.D., have joined the company's board of directors. In addition, former Allergan Vice President and Therapeutic Area Head for ophthalmology, Rhett Schiffman, M.D., M.S., M.H.SA. has joined the company as its Chief Medical Officer. Along with the Neurotech team, Drs. de Juan and Kaplan will help advance the company's technology platform through the clinical development stage toward market availability. As CMO, Dr. Schiffman will lead the overall clinical development strategy as well as the design and execution of the various clinical programs at Neurotech. Eugene de Juan is a retinal surgeon, inventor and entrepreneur. He serves as Vice-Chairman of ForSight Labs. Lester Kaplan was Executive Vice President and President, Research & Development, and a board member of Allergan, Inc. Rhett Schiffman was most recently Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan.
Neurotech Pharmaceuticals, Inc. Appoints James Mazzo as Executive Chairman
Aug 6 13
Neurotech Pharmaceuticals, Inc. announced that James Mazzo was appointed the company's Executive Chairman. Mazzo, a long time leader in the ophthalmic industry, is the former CEO of Abbott Medical Optics (AMO). As Executive Chairman, Mazzo will engage with the Neurotech team to advance the company's novel technology platform through the clinical development stage toward market availability. Jim Mazzo's 35-year career in the healthcare industry includes seven years as Chairman, President and CEO of Advanced Medical Optics (AMO). He was previously with Allergan for over 20 years in a variety of expanding roles, working and living in the U.S., England, Italy and Canada.
Neurotech Launches Neurotech Recovery-Back
Jul 25 12
Neurotech is introducing the Neurotech Recovery-Back, an innovative and non-invasive device designed to help manage low back pain and rehabilitate the low back and abdominal muscles. Neurotech Recovery-Back device helps control and treat back pain using two clinically proven therapies, TENS (transcutaneous electrical nerve stimulation) and NMES (neuromuscular electrical stimulation). The comfortable and easy-to-wear device integrates two conductive garments that relieve both chronic and acute low back pain. The patient uses a hand-held controller to control the amount of stimulation delivered to the lower back and abdominal muscles. Neurotech Recovery-Back is cleared by the FDA and is only available by prescription.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|